Inactive Instrument

Provention Bio, Inc.

PRVB

US74374N1028

Provention Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 05, 2022 at 07:29 am EDT

Provention Bio, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 21.97 million compared to USD 32.44 million a year ago. Basic loss per share from continuing operations was USD 0.35 compared to USD 0.52 a year ago.

Latest news about Provention Bio, Inc.

Provention Bio, Inc.(NasdaqGS:PRVB) dropped from S&P Pharmaceuticals Select Industry Index	23-05-02	CI
Provention Bio, Inc.(NasdaqGS:PRVB) dropped from S&P Global BMI Index	23-05-02	CI
Provention Bio, Inc.(NasdaqGS:PRVB) dropped from S&P TMI Index	23-05-02	CI
Improving Confidence in Eurozone Economy Lifts French Shares Amid Q1 Results Outpour	23-04-27	MT
Sanofi Completes Provention Bio Acquisition	23-04-27	MT
Provention Bio, Inc. Appoints Debora Pellicano as Chief Financial Officer	23-04-27	CI
Provention Bio, Inc. Announces Management Changes	23-04-27	CI
Sanofi Closes $3 Billion Acquisition of Provention Bio	23-04-27	MT
Provention Bio, Inc.(NasdaqGS:PRVB) dropped from NASDAQ Composite Index	23-04-27	CI
Sanofi completed the acquisition of 97.1% stake in Provention Bio, Inc..	23-04-26	CI
Sanofi Secures US Antitrust Clearance for $2.9 Billion Provention Bio Takeover	23-04-26	MT
Provention Bio, Inc.(NasdaqGS:PRVB) dropped from NASDAQ Biotechnology Index	23-04-26	CI
Sanofi wins US drug control from AstraZeneca in Sobi deal	23-04-11	AN
Sanofi Extends Offer Period for Provention Bio Takeover Amid US Regulatory Review	23-04-11	MT
North American Morning Briefing : Some Calm -2-	23-03-16	DJ
HC Wainwright Downgrades Provention Bio to Neutral From Buy, Adjusts Price Target to $25 From $16	23-03-15	MT
North American Morning Briefing : Futures Deep in -3-	23-03-15	DJ
SMBC Nikko Downgrades Provention Bio to Neutral From Outperform, Raises Price Target to $25 From $15	23-03-14	MT
Jefferies Downgrades Provention Bio to Hold From Buy, Price Target is $25	23-03-14	MT
Healthcare Shares Climb Amid Deal News -- Healthcare Roundup	23-03-13	DJ
Sector Update: Health Care Stocks Close with Solid Monday Gains	23-03-13	MT
Sector Update: Health Care Maintaining Monday Rebound	23-03-13	MT
Top Midday Gainers	23-03-13	MT
Sector Update: Health Care	23-03-13	MT
Sector Update: Health Care Stocks Advance in Early Monday Morning Trade	23-03-13	MT

Chart Provention Bio, Inc.

Duration

Period

More charts

Company Profile

Provention Bio, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing the development and commercialization of investigational therapies that intercept and prevent debilitating and life-threatening immune-mediated diseases. The Company's pipeline includes TZIELD (teplizumab-mzwv), PRV-3279, Ordesekimab and PRV-101. TZIELD (teplizumab-mzwv) is a CD3-directed antibody indicated to delay the onset of stage three T1D in adults and pediatric patients aged eight years and older with stage two T1D. It is also developing TZIELD for use in stage three newly diagnosed T1D patients. PRV-3279 is a humanized bispecific scaffold molecule targeting the B-cell surface proteins for the treatment of SLE and for the prevention of immunogenicity of biotherapeutics. Ordesekimab is a human anti-interleukin 15 (IL-15) monoclonal antibody for the treatment of gluten-free diet non-responsive celiac disease. PRV-101 is a CVB vaccine to prevent acute CVB infections.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	-4.17%	86.99B
SAMSUNG BIOLOGICS CO.,LTD.	+4.34%	40.68B
BIOGEN INC.	-24.27%	28.61B
UCB	+51.27%	24.1B
BIOMARIN PHARMACEUTICAL INC.	-5.30%	17.37B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-32.11%	13.72B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-5.10%	12.49B
INCYTE CORPORATION	-14.44%	12B
SWEDISH ORPHAN BIOVITRUM AB	-3.22%	7.94B

Biopharmaceuticals